The Modern Lipid Playbook Part 2: THE TESTING — Why Your Lipid Panel Isn't Enough

The Modern Lipid Playbook Part 2: THE TESTING — Why Your Lipid Panel Isn't Enough 🚨 2026 ACC/AHA Dyslipidemia Guidelines just dropped — the first update i…

Published April 15, 202650:16The Longevity Show

David was 62, exercised, ate well, saw his doctor every year, and had an LDL in the 40s — below even aggressive targets. He had been told he was fine for 25 years. When Dr. Lin ordered the tests nobody had run, his widowmaker artery was 75–99% blocked and his calcium score was 1,522, nearly four times the threshold for severe.

Part two of the lipid series is about why that happens, and it is largely a story about the wrong tests being ordered first. The standard panel counts cholesterol cargo rather than the particles that actually lodge in artery walls. The stress test — the one nearly everyone gets first — only detects blockages above 70%, while roughly two thirds of heart attacks originate from lesions narrowed less than 50%.

Three weeks before recording, eleven medical specialty societies rewrote the cholesterol testing guidelines for the first time in eight years, making ApoB and Lp(a) standard of care rather than optional. The episode walks the full hierarchy — which blood tests, then which imaging, in what order, and what each one is blind to.

Before you watch

LDL-C counts cargo; ApoB counts vehicles, and the vehicles cause the damage. Every atherogenic particle — LDL, VLDL, IDL, Lp(a) — carries exactly one ApoB. Ten trucks with ten boxes each and fifty motorcycles with two each produce the same LDL-C and five times the traffic. Roughly one in five people are discordant, and two people with an identical LDL-C of 110 can have ApoB of 80 or 140.
Your LDL-C was probably calculated, not measured. The 1972 Friedewald equation assumes a fixed triglyceride-to-VLDL ratio that isn't true for everyone. Textbooks say it fails above 400 triglycerides; in practice it starts underestimating LDL-C by around 18 mg/dL above 150 — and the people it fails on are exactly those with metabolic syndrome who most need accuracy.
ApoB costs about $15 and is now guideline-recommended. Targets discussed: under 65 for high risk per the ESC, with much of the longevity field pushing under 60 and some under 50. If your doctor won't order it, most consumer lab platforms will.
Skip the expensive NMR advanced panel. It correlates with ApoB at r = 0.90–0.95, so you are paying $200-plus for information a $15 test already gives you. No randomised trial has ever used LDL particle size to guide therapy.
A stress test is close to useless as a screening tool, and passing one may be the most dangerous reassurance in cardiology. It only detects flow limitation above roughly 70% stenosis, while most heart attacks come from smaller, inflamed, lipid-rich plaques that rupture. Arteries also remodel outward to accommodate plaque until about 40% of the wall is involved, so the lumen looks normal. Exercise ECG sensitivity is 68%, dropping to around 60% in women with two to three times the false positive rate.
A calcium score of zero does not mean clean arteries — it means no calcified plaque. Among people with CAC of zero who go on to CCTA, 9.3% have atherosclerosis, and nearly half of those have significant stenosis. Calcification is a late-stage process, so younger patients preferentially have exactly the non-calcified plaque CAC cannot see. Dr. Lin's own CAC was zero alongside an ApoB of 128.
If your calcium score rises on a statin, that is usually good news. Statins stabilise plaque by calcifying it, converting dangerous soft plaque into stable calcified plaque. The number going up can mean the drug is working.
CCTA with AI plaque analysis is the definitive test, and the evidence is strong. SCOT-HEART randomised 4,146 patients and found a 41% reduction in coronary death or non-fatal heart attack at five years, sustained at ten. AI platforms quantify plaque volume and composition — low-attenuation plaque under 30 Hounsfield units corresponds to the lipid-rich necrotic core that actually ruptures, and predicts events better than calcified plaque does.
Fasting insulin and hs-CRP fill in the environment that determines whether particles turn into plaque. By the time fasting glucose is abnormal you have often been insulin resistant for a decade; each standard deviation increase in HOMA-IR was associated with 46% higher cardiovascular risk across 65,000 subjects. On the inflammatory side, JUPITER showed a 44% event reduction in people with normal LDL but elevated CRP, and CANTOS reduced events 15% by targeting inflammation without touching cholesterol at all.
Two markers deserve less attention than they get. Raising HDL has failed repeatedly — torcetrapib raised it 72% and the trial was stopped early because more patients died; HDL is a thermometer, not the fever. And lowering triglycerides without lowering ApoB does nothing: PROMINENT cut triglycerides 26% in 10,000 patients for zero cardiovascular benefit.

Chapters

Questions

My cholesterol panel is normal. Is that enough?

Probably not, and this is the episode's central point — around half of heart attacks occur in people with normal LDL-C. The standard panel measures cholesterol content rather than particle count, and calculates rather than measures LDL. At minimum, add ApoB and a one-time Lp(a). Dr. Lin's suggested baseline panel — ApoB, Lp(a), standard lipids, fasting insulin, hs-CRP and A1c — runs around $100 out of pocket and is worth having by 25.

I passed a stress test. Doesn't that mean my arteries are fine?

No, and this is where the false reassurance is most dangerous. A stress test asks only whether blood flow is restricted right now, which requires roughly 70% narrowing to show up. About two thirds of heart attacks come from lesions under 50% narrowed — smaller, inflamed plaques that rupture unpredictably. Arteries also expand outward to accommodate plaque, keeping the channel open and the test normal. A stress test is a reasonable functional test once you know you have plaque; it is a poor way to find out whether you do.

What imaging should I actually get, and in what order?

Bloods first because they are cheapest and identify who needs imaging. Then a coronary calcium score at around $100 — useful, widely available, and genuinely good at risk stratification. Then CCTA with AI plaque analysis, which is the definitive test because it visualises the artery wall and characterises plaque type rather than just calcium. If your CAC is above zero, get the CCTA. If it is zero but you have real risk factors, still get it if you can.

Who should not get a CCTA?

It is not universally appropriate. Severe kidney disease with eGFR under 30 or a true iodine allergy make contrast a problem. Atrial fibrillation and heart rates above 65 degrade the images, as does a BMI over 40. Very heavy calcification above a CAC of 1,000 creates blooming artefact that overestimates stenosis. Radiation is 1–5 mSv — roughly a mammogram or two, and far below nuclear stress testing at 11–24 — but it is not zero, so annual repeats are the sensible ceiling. Availability and cost remain the real barriers.

Is any of this covered by insurance?

Increasingly. ApoB and Lp(a) are now standard of care after the 2026 guideline rewrite. CCTA has carried a class I recommendation for intermediate-risk patients since 2021. And a new CPT code for AI-driven plaque quantification went live on 1 January 2026 with permanent Medicare reimbursement around $1,021, with UnitedHealthcare and Cigna announcing coverage. The remaining gap is screening people without symptoms, which is still largely self-pay — though $300–600 self-pay CCTA is increasingly available in major cities.

Why does this matter more for women?

Two reasons. Stress testing performs worse in women — around 60% sensitivity with two to three times the false positive rate, so women are both more likely to be falsely reassured and more likely to get an unnecessary catheterisation. And atherosclerosis is systemic, not just coronary: the WISE study found women with chest pain, evidence of ischaemia and clean angiograms had significantly worse outcomes than expected, with roughly one in three cardiac deaths in women occurring in people whose angiogram looked clean. Microvascular disease is measurable via coronary flow reserve on PET, but is rarely looked for.

The Longevity Letter